Results 81 to 90 of about 3,463,039 (240)

Dual pKa Lipid Nanoparticles for Lung‐tropic mRNA Delivery and pH‐Programmed Endosomal Escape

open access: yesAdvanced Science, EarlyView.
Lipid nanoparticles’ bottleneck lies in low endosomal escape efficiency and liver‐dominant delivery after intravenous administration. To overcome these limitations, we present a stepwise pH‐programmed lipid nanoparticle system enabled by our newly synthesized ionizable lipid.
Seong Gi Lim   +12 more
wiley   +1 more source

Potential of Nanoparticle‐Based Phototherapies for Future Treatment of Uveal Melanoma

open access: yesAdvanced Science, EarlyView.
This review evaluates nanoparticle‐based phototherapies for uveal melanoma, highlighting emerging strategies to enhance tumor targeting, light delivery, and treatment precision. Preclinical data indicate improved efficacy and reduced toxicity, supporting their potential to enhance localized treatment and future translational advances. (Generated by the
Emilie Lambert   +8 more
wiley   +1 more source

Gradient between the free hepatic vein pressure and the central venous pressure (FHVP-CVP).

open access: yes, 2015
Large symbols represent mean FHVP-CVP gradient values and bars represent standard deviation. Small symbols represent individual FHVP-CVP gradient values. Median FHVP-CPV gradients are similar in conventional and piggyback techniques (p = 0.74).
Ernesto Sasaki Imakuma (761558)   +3 more
core   +1 more source

Structural Basis of Shiga Toxin Neutralization by Human Antibodies Targeting Canonical Receptor‐Binding and Non‐Canonical Assembly Sites

open access: yesAdvanced Science, EarlyView.
Cryo‐electron microscopy structures reveal two distinct neutralization mechanisms of fully human monoclonal antibodies targeting the Shiga toxin 1a B subunit. RDS059 occludes the Gb3 receptor‐binding site, whereas RDS045 engages a lateral quaternary epitope to disrupt holotoxin assembly.
Jianting Ke   +10 more
wiley   +1 more source

Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis.

open access: yesPLoS ONE, 2019
BACKGROUND:Prostanoids are important regulators of platelet aggregation and thrombotic arterial diseases. Their involvement in the development of portal vein thrombosis, frequent in decompensated liver cirrhosis, is still not investigated.
Alexander Queck   +15 more
doaj   +1 more source

The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery [PDF]

open access: yes, 2019
Background & Aims: Surgery in cirrhosis is associated with a high morbidity and mortality. Retrospectively reported prognostic factors include emergency procedures, liver function (MELD/Child-Pugh scores) and portal hypertension (assessed by indirect ...
Josep Fuster   +46 more
core   +1 more source

Uhrf1‐Mediated PKM2 Degradation via Ubiquitination Alleviates Inflammation and Pyroptosis in Inflammatory Bowel Disease

open access: yesAdvanced Science, EarlyView.
Uhrf1‐mediated PKM2 ubiquitination and degradation repressed the nuclear translocation of PKM2, and EPT served as a molecular glue capable of targeting the Uhrf1–PKM2 complex to alleviate the IBD course, suggesting that the Uhrf1–PKM2 axis was a previously unrecognized strategy for treating IBD.
Juan Zhang   +9 more
wiley   +1 more source

Risk factors and predictors of recurrent variceal bleeding in cirrhotic patients awaiting transplantation

open access: yesВестник трансплантологии и искусственных органов
Objective: to identify the risk factors and predictors of recurrent variceal hemorrhage in cirrhotic patients awaiting liver transplantation (LT).Materials and methods.
V. L. Korobka   +5 more
doaj   +1 more source

On 'spot' evolution under an adverse pressure gradient [PDF]

open access: yes, 2001
The unsteady travelling 'spots' or spot-like disturbances are produced, in an otherwise planar boundary layer, by an initial impulse/blip, from wall forcing or from nearby external forcing. Theory and computations are described for the evolving spot-like
Timoshin, SN, Smith, FT
core  

Home - About - Disclaimer - Privacy